Search

everythinglearnresearchcommunity

for

Search:↓

The medication cyproterone acetate/ethinylestradiol is usually prescribed correctly for acne after other treatments don't work.

Cyproterone acetate may cause liver cancer at high doses, but is considered safe at recommended doses for approved uses.

The treatment was effective for lupus nephritis with manageable side effects.

PEGylated liposomal doxorubicin improves cancer treatment effectiveness and reduces side effects like heart damage and hair loss.

Nilotinib can cause keratosis pilaris, a skin condition.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.

Cyclophosphamide can cause serious short-term and long-term side effects, including increased cancer risk and infertility.

Upadacitinib effectively treats pyoderma gangrenosum.

The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.

Analog 23 is a promising compound for prostate cancer treatment.

New compounds were made that are promising for prostate cancer therapy.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

Rapid virilization should be checked for possible ovarian or adrenal cancer.

GI197111X is best dissolved in Capmul MCM for trials.

The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.

Low-dose flutamide improved hirsutism and satisfaction in women but had common side effects, causing some to stop treatment.

Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

Multicomponent crystals in microneedles improve drug delivery for hair loss treatment.

The combination treatment showed a higher response rate but no significant survival benefits.